Monthly Archives: November 2026

Wastewater and Effluent Treatment for Peptide Manufacturing (2026)

Peptide synthesis and purification produce effluent that is small in volume and difficult in composition: high organic load from residual solvents, variable pH, salt peaks from ion-exchange regeneration and cleaning chemicals from changeover. This guide covers what the waste stream actually contains, how to characterise it before choosing a treatment train, and what a discharge […]

Dangerous Goods Classification and IATA Packing for Peptide Shipments (2026)

Peptides are usually not dangerous goods, but the shipments that carry them often are: dry ice is a regulated substance, some solvents and preservatives are flammable, and biological materials have their own classification. This guide explains how to decide whether a consignment is regulated, which packing instruction applies, and where courier acceptance fails in practice. […]

Freedom to Operate and Patent Clearance for Peptide Products (2026)

Freedom to operate is a negative opinion, not a certificate: it says that no third-party patent found in a defined search appears to cover a defined product in a defined market. Getting that opinion right depends on searching the patent families that actually matter, reading claims rather than abstracts, and keeping the analysis current as […]

Liability Caps and Indemnity Clauses for Peptide Supply Agreements (2026)

An uncapped indemnity in a supply agreement is not a risk allocation, it is a transfer of the buyer’s entire downstream exposure to a supplier who cannot carry it. This guide explains how caps are set, which liabilities have to stay uncapped, how consequential loss clauses are actually read, and what insurance has to exist […]

Performance Bonds and Securing Payment Terms for Peptide Supply (2026)

A performance bond is supposed to pay when a supplier fails to deliver, but the instrument only works if the wording is unconditional, the issuing bank is acceptable and the claim route is understood before anything goes wrong. This guide separates the bond from the letter of credit, sets out the wording that actually pays, […]

Exclusive Territory and Gray Market Control for Peptide Distribution (2026)

An exclusive territory is a promise about where product may be sold, and it is worthless unless the agreement also defines the territory precisely, sets conditions the distributor must keep meeting, and gives the supplier a way to detect and stop product that leaves the channel. This guide covers the four mechanisms that make exclusivity […]

Order Change and Expedite Handling for Peptides (2026)

Most supply failures are not made at the factory; they are made when an order changes after the material has been committed. This guide sets out how to handle quantity changes, date pulls and specification amendments without breaking either the schedule or the quality record. Key Research Points A change is a new commitment, and […]

Force Majeure and Contract Termination for Peptide Supply (2026)

Supply contracts are usually written for the ordinary case and tested in the extraordinary one. This guide explains how force majeure, termination and exit provisions actually operate in peptide supply agreements, and where the wording decides who carries the loss. Key Research Points Force majeure excuses performance only for the event and period defined, and […]

Laboratory Information Management System Implementation for Peptides (2026)

A LIMS changes how samples, results and specifications move through a laboratory, and most implementation problems are process problems that the software exposes. This guide covers scoping, validation, data migration and the go-live decisions that determine whether the system is trusted or worked around. Key Research Points The system should be specified from the laboratory’s […]